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Abstract: Joint modelling of longitudinal and survival data is increasingly used in clinical trials on
cancer. In prostate cancer for example, these models permit to account for the link between longitudinal
measures of prostate-specific antigen (PSA) and the time of clinical recurrence when studying the risk of
relapse. In practice, multiple types of relapse may occur successively. Distinguishing these transitions
between health states would allow to evaluate, for example, how PSA trajectory and classical covariates
impact the risk of dying after a distant recurrence post-radiotherapy, or to predict the risk of one spe-
cific type of clinical recurrence post-radiotherapy, from the PSA history. In this context, we present a
joint model for a longitudinal process and a multi-state process which is divided into two sub-models: a
linear mixed sub-model for longitudinal data, and a multi-state sub-model with proportional hazards for
transition times, both linked by shared random effects. Parameters of this joint multi-state model are es-
timated within the maximum likelihood framework using an EM algorithm coupled to a quasi-Newton
algorithm in case of slow convergence. It is implemented under R, by combining and extending the
mstate and JM packages. The estimation program is validated by simulations and applied on pooled
data from two cohorts of men with localized prostate cancer and treated by radiotherapy. Thanks to
the classical covariates available at baseline and the PSA measurements collected repeatedly during the
follow-up, we are able to assess the biomarker’s trajectory, define the risks of transitions between health
states, and quantify the impact of the PSA dynamics on each transition intensity.
Keywords: Joint modelling; Longitudinal process; Multi-state process; Prostate cancer; R; Shared ran-
dom effects.
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21 Introduction
In longitudinal health studies, marker data are usually collected at repeated measurement times until the
occurrence of an event such as disease relapse or death, with the perspective to study the link between
these two correlated processes or use the information brought by the marker’s dynamics to explain or
predict the time to event. In such analyses, the repeated measurements of the marker should not be
considered as a standard time-dependent covariate in a survival model (Andersen and Gill, 1982; Fisher
and Lin, 1999) because the marker is an internal outcome measured with error and at discrete times
whereas the Cox model assumes to know the exact values of the explanatory variables for all individuals
at risk at each event time. To counteract these weaknesses, the two processes can be modelled jointly
(Faucett and Thomas, 1996; Wulfsohn and Tsiatis, 1997). The principle is to define two sub-models
(one mixed sub-model for the longitudinal data and one survival sub-model for the time-to-event data)
and link them using a common latent structure. The shared random effect models, notably developed by
Tsiatis and Davidian (2004), are the most popular joint models. They usually assume that a function of
the random effects from the linear mixed model is included as covariates in the survival model. Thus,
longitudinal and survival processes share the same random effects, and the effect of the dynamics of the
marker on the risk of event can be deduced.
In prostate cancer, the joint modelling method is very useful. The prostate-specific antigen (PSA),
which is a protein secreted by the prostate, is found to be over-expressed in the presence of prostate can-
cer. This blood-based longitudinal tumour marker is commonly used by clinicians to monitor patients
with localized prostate cancer following treatment (radiation therapy or surgery) in order to detect sub-
clinical presence of disease. Proust-Lima et al. (2008) , Taylor et al. (2005) and Yu et al. (2008) showed,
through various types of joint models, that the dynamics of this biomarker, along with the pre-treatment
PSA level and other factors measuring the aggressiveness of cancer cells and the extent of the tumour,
were risk factors for progression and permitted one to dynamically predict (i.e. using PSA to adapt
prediction over time) the risk of clinical relapse.
In practice, a patient may experience a succession of clinical progression events with for example
a local recurrence, followed by a distant metastatic recurrence and then death. So, instead of the oc-
currence of a single clinical event, the progression of prostate cancer should be defined as a multi-state
3process with a focus on the transitions between clinical states and the impact of the biomarker dynamics
on it. This is essential to understand and predict accurately the course of the disease, and it is of partic-
ular relevance for the clinicians that need to distinguish the different types of events in order to properly
adapt the treatment.
Some authors already extended the classical framework of joint modelling to multiple time-to-event
data. Chi and Ibrahim (2006) proposed a joint model for multivariate longitudinal data and multivariate
survival data. Liu and Huang (2009) and Kim et al. (2012) looked into the simultaneous study of three
correlated outcomes: longitudinal data, times of recurrent events and time of terminal event. Elashoff
et al. (2008) and Rizopoulos (2012) extended the joint model to competing risks survival data, which
allows to characterize the cause of survival event. Dantan et al. (2011) presented a joint model with
latent state for longitudinal data and time-to-illness and time-to-death data. Recently, Andrinopoulou
et al. (2014) studied simultaneously two longitudinal markers and competing events. However, the joint
study of longitudinal and multi-state data has never been proposed and implemented. Thus, we introduce
a joint model with shared random effects for repeated measurements of a longitudinal marker and times
of transitions between multiple states. It consists in a linear mixed model and a multi-state model with
transition-specific proportional intensities, both linked by shared random effects.
The computational aspect is the main obstacle in the development of joint models with shared ran-
dom effects. As explained by Gould et al. (2014), the R package JM, developed by Rizopoulos (2010),
has enabled many advances in the use of joint modelling, particularly through efficient numerical inte-
grations. On the other hand, the R package mstate, developed by De Wreede et al. (2010), provides
estimation of multi-state models. In the present work, we combine and adapt these two packages in
order to estimate joint multi-state models. Thus, the implementation is easy and effective. Through the
adaptation of the jointModel() function of the JM package, our approach uses the maximum likelihood
approach, which is performed using the EM algorithm coupled to a quasi-Newton algorithm in case of
slow convergence. The software advantage is that it keeps the features, syntax and outputs of JM.
The paper is organized as follows. Section 2 presents the joint model for longitudinal and multi-
state processes. The estimation and implementation procedures are detailed in Section 3. The joint
multi-state model has been validated by simulations, as detailed in Section 4. We apply our model on a
detailed example of two cohorts of men with prostate cancer in Section 5. A brief discussion is given in
4Section 6.
2 Joint multi-state model
2.1 Notations
For each individual i, a longitudinal process and a multi-state process are observed. Let {Ei(t), t ≥ 0} be
the multi-state process where Ei(t) denotes the occupied state by subject i at time t and takes values in the
finite state space S = {0, 1, . . . ,M}. It is assumed that the multi-state process is continuous and observed
between the left truncation time Ti0 and the right censoring time Ci, so that the observed process is
Ei = {Ei(t),Ti0 ≤ t ≤ Ci}. We further consider that Ei is a non-homogeneous Markov process. The
Markov property ensures that the future of the process depends only on the present state and not the
past state, i.e. Pr (Ei(t + u) = k|Ei(t) = h, {Ei(s), s < t}) = Pr (Ei(t + u) = k|Ei(t) = h) ,∀h, k ∈ S ,∀u ≥ 0
(De Wreede et al. (2010)), and the non-homogeneous property guarantees that the time since Ti0 impacts
the future evolution of the process. Let us consider Ti =
(
Ti1,Ti2, . . . ,Timi
)> the vector of the mi ≥ 1
observed times for the individual i, with Tir < Ti(r+1),∀r ∈ {0, . . . ,mi − 1}, and where > denotes the
transpose vector. If the last observed state for subject i (Ei(Timi)) is absorbing, that is it is impossible
to leave it once entered (typically death), we observe mi direct transitions. Otherwise, Timi equals Ci
the right censoring time and we observe mi − 1 direct transitions. We define by δi = (δi1, . . . , δimi)> the
vector of observed transition indicators, with δi(r+1) equals 1 if a transition is observed at time Ti(r+1)
(i.e. Ei(Tir) , Ei(Ti(r+1))) and 0 otherwise, ∀r ∈ {0, . . . ,mi − 1}. For each patient i, we also observe
Yi =
(
Yi1, . . . ,Yini
)> the vector of ni measures of the marker collected at times ti1, . . . , tini , with tini ≤ Timi .
2.2 Joint multi-state model formulation
The joint multi-state model is decomposed into two sub-models : a linear mixed sub-model for the
longitudinal data (repeated measurements of the biomarker) and a multi-state model with proportional
hazards for the event history data (transition and censoring times), both linked by shared random effects.
52.2.1 Longitudinal sub-model
To model the trajectory of the longitudinal marker, we use a linear mixed model. Under Gaussian as-
sumptions, we assume that Yi j the observed measure of the marker at time point ti j is a noisy measure of
the true measure Y∗i (ti j). This non-observed measure Y
∗
i (ti j) is explained according to time and covari-
ates, at the population level, with fixed effects β and at the individual level, with random effects bi that
take into account the correlation between repeated measures of the same individual:
Yi j = Y∗i (ti j) + i j
= XLi (ti j)
>β + Zi(ti j)>bi + i j, (1)
with XLi (ti j) and Zi(ti j) the vectors of possibly time-dependent covariates associated respectively with
the p-vector of fixed effects β and the q-vector of random effects bi, bi ∼ N(0,D). Note that i =(
i1, . . . , ini
)> ∼ N(0, σ2Ini) where I is the identity matrix; i and bi are independent.
2.2.2 Multi-state sub-model
To model the transition times, we use a Markov multi-state model with proportional hazards that takes
into account the marker’s dynamics through the shared random effects bi. Thus, for the transition from
state h ∈ S to state k ∈ S , the transition intensity at time t takes the form:
λihk(t|bi) = limdt→0
Pr(Ei(t + dt) = k|Ei(t) = h; bi)
dt
= λhk,0(t) exp(XS >hk,i γhk + Whk,i(bi, t)
>ηhk), (2)
with λhk,0(.) the parametric baseline intensity (Weibull, piecewise constant or B-splines for example) and
XShk,i the vector of prognostic factors associated with the r-vector of coefficients γhk. The multivariate
function Whk,i(bi, t) defines the dependence structure between the longitudinal and multi-state processes.
We can choose Whk,i(bi, t) = Y∗i (t) (the true current level of the marker), or Whk,i(bi, t) = ∂Y
∗
i (t)/∂t (the
true current slope), Whk,i(bi, t) =
(
Y∗i (t), ∂Y
∗
i (t)/∂t
)>
(both), or any other function of the random effects
in the context under study. Thus, the s-vector of coefficients ηhk quantifies the impact of the longitudinal
marker’s dynamics on the transition intensity between states h and k.
63 Estimation
3.1 Likelihood
The parameters of this joint model are estimated in the maximum likelihood framework. Since the
longitudinal and multi-state processes are independent conditionally on the random effects, the complete
observed likelihood is obtained through the product of the individual contributions to the likelihood for
the N individuals as:
L(θ) =
N∏
i=1
∫
Rq
fY (Yi|bi; θ) fE(Ei|bi; θ) fb(bi; θ) dbi, (3)
where θ is the vector of all the parameters contained in (1) and (2), and f (.) is a probability density
function.
In the longitudinal sub-part, described by the linear mixed model (1), the conditional longitudinal
outcomes are such that:
fY (Yi|bi; θ) = 1(
2piσ2
)ni/2 exp
−‖Yi − XL >i β − Z>i bi‖22σ2
 , (4)
where ||x|| denotes the Euclidean norm of vector x, XLi is the matrix of covariates with row vectors
XLi (ti j)
T , j = 1, . . . , ni, and likewise Zi = {Zi(ti j)}.
For the multi-state side, let Pihk(s, t) be the transition probability from state h to state k between the
times s and t for individual i, i.e. Pihk(s, t) = Pr(Ei(t) = k|Ei(s) = h). For each r ∈ {0, . . . ,mi − 1},
the continuity and Markov assumptions imply that the individual i remains in state Ei(Tir) between the
times Tir and Ti(r+1) with probability PiEi(Tir),Ei(Tir)(Tir,Ti(r+1)|bi), and if Ti(r+1) is an observed transition
time, he transits to state Ei(Ti(r+1)) with intensity λiEi(Tir),Ei(Ti(r+1))(Ti(r+1)|bi). By conditioning on Ei(Ti0),
this translates in the individual contribution to the likelihood:
fE(Ei|bi; θ) =
mi−1∏
r=0
[
PiEi(Tir),Ei(Tir)(Tir,Ti(r+1)|bi) λiEi(Tir),Ei(Ti(r+1))(Ti(r+1)|bi)
δi(r+1)
]
=
mi−1∏
r=0
[
exp
(∫ Ti(r+1)
Tir
λiEi(Tir),Ei(Tir)(u|bi) du
)
λiEi(Tir),Ei(Ti(r+1))(Ti(r+1)|bi)
δi(r+1)
]
(5)
7with λihh(t) = −
∑
k,k,h λ
i
hk(t). The possible delayed entry is here ignored by conditioning on Ei(Ti0).
Linking the longitudinal and multi-state sub-parts, the random effects bi follow a multivariate Gaus-
sian distribution such that:
fb(bi; θ) =
1
(2pi)q/2det(D)1/2
exp
−b>i D−1bi2
 . (6)
3.2 Implementation
The joint multi-state model has been implemented under R, via the combination of two well-known
packages: mstate for the multi-state models and JM for the joint models with shared random effects.
To fit semi-parametric Markov multi-state models, mstate consists first of preparing the database for
multi-state analysis, more specifically by defining each patient’s history as a series of rows, one for each
transition at risk for each individual (in contrast with only one data record (row) per individual in a
classical survival analysis). By stratifying on the transition type, the standard coxph() function of the
R package survival can be used to fit transition-specific Cox models. With standard longitudinal and
time-to-event data, the JM package initialises the values of parameters from the function lme() (nlme
package) for the longitudinal sub-part and coxph() (survival package) for the survival sub-part. Then,
the function jointModel() carries out the estimation procedure.
So by replacing the standard call to coxph() by the call to coxph() on prepared data by mstate, an
extended jointModel() function, called JMstateModel(), carries out the estimation procedure. The
implementation procedure is thus distinguished in four steps:
• lme() function to initialise the parameters in the longitudinal sub-model;
• mstate package to adapt the data to the multi-state framework;
• coxph() function, on the prepared data, to initialise the parameters in the multi-state sub-model;
• JMstateModel() function to estimate all the parameters of the joint multi-state model.
A detailed example is given in Appendix C, and full detailed examples are available on https://
github.com/LoicFerrer/JMstateModel/.
83.3 Algorithm
The JMstateModel() function computes and maximises the likelihood adapted to the multi-state data
using integration and optimisation algorithms available in the JM package. Thus, the procedure combines
an EM algorithm coupled to a quasi-Newton algorithm if the convergence is not achieved. Furthermore,
the integral with respect to time in (5) and the integral with respect to the random effects in (3) do not
have an analytical solution. These integrals are approached by numerical integration. The integrals
over time are approximated using Gauss-Kronrod quadratures, and the integrals over the random effects
using pseudo-adaptative Gauss-Hermite quadratures. Inference is provided by asymptotic properties for
maximum likelihood estimators; the variance-covariance matrix of the parameter estimates is based on
the inverse of the Hessian matrix. More details on the optimisation procedure, the EM algorithm and the
numerical integrations are available in Rizopoulos (2012).
4 Simulation study
The simulation study aimed to validate the estimation program described previously.
4.1 Data generation
For each subject i = 1, . . . , 1500 of the 500 replicates, the longitudinal and multi-state data were gener-
ated according to the joint multi-state model defined as:

Yi j = Y∗i (ti j) + i j
= (β0 + β0,XXi + bi0) + (β1 + β1,XXi + bi1) × ti j + i j,
λihk(t|bi) = λhk,0(t) exp
(
γhkXi + ηhk,levelY∗i (t) + ηhk,slope∂Y
∗
i (t)/∂t
)
,
(7)
where the multi-state process that included three states (h, k ∈ {0, 1, 2}) and three transitions is described
in Figure 1.
[Figure 1 about here.]
9First, Xi and bi were generated according to normal distributions with respectively mean 2.04 and
variance 0.5, and mean vector
00
 and variance-covariance matrix
 0.35 −0.04−0.04 0.06
. The times of mea-
surements were generated such as ti j = 0, 0.33, 0.67, . . . , 16.33, and i j was generated from a stan-
dard normal distribution. The log baseline intensities were linear combinations of cubic B-splines
with the same knot vector (0.004, 4.120, 7.455, 10.908, 18.201)> for the three transitions, and the vec-
tors of spline coefficients (−9.200,−3.500,−5.000, −3.900,−3.500,−2.500,−2.000)T for the transition
0 → 1, (−9.860,−4.472,−5.128,−3.486, −2.457,−0.989,−0.715)> for the transition 0 → 2, and
(−2.527,−2.170,−2.492,−2.156, −1.228,−0.955,−0.161)> for the transition 1→ 2. Parameters values
and knot locations were chosen according to the application data described in Section 5.
The procedure to generate the vector of observed times Ti =
(
Ti1, . . . ,Timi
)> was inspired by
Beyersmann et al. (2011) and Crowther and Lambert (2013). For each individual i, the censoring
time Ci was generated from an uniform distribution on [1, 25], and the vector of true transition times
T ∗i =
(
T ∗i,01,T
∗
i,02,T
∗
i,12
)>
was generated according to the following procedure: (1) three random numbers
ui,01, ui,02 and ui,12 were generated from three independent standard uniform distributions; (2) T ∗i,01 and
T ∗i,02 were generated by solving
∫ T ∗i,0k
0 λ
i
0k(ν0k|bi) dν0k + log(ui,0k) = 0, for k = 1, 2, through the Brent’s
univariate root-finding method (Brent, 1973); (3) then, the true transition time T ∗i,12 was generated via∫ T ∗i,12
T ∗i,01
λi12(ν12|bi) dν12+log(ui,12) = 0. Finally, by comparing T ∗i andCi, the vector Ti, which characterizes
the multi-state process, was deduced.
The longitudinal measurements, generated from the linear mixed sub-model, were truncated at Ti1
the first observed time of the multi-state process.
4.2 Estimated model
The estimation model was the model defined in (7) with bi ∼ N

00
 ,
D11 D12D12 D22

 and i j ∼ N(0, σ2).
The log baseline intensities were approximated by a linear combination of cubic-splines with three
internal knots placed at the quantiles of the observed times.
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4.3 Simulation results
The simulations results were obtained through 500 replicates of 1500 individuals. Each joint multi-
state model was estimated using 3, 9 and 15 pseudo-adaptative Gauss-Hermite quadrature points. The
simulation results are presented in Table 4.
These results were very satisfying with unbiased estimates and correct 95% coverage rates. They
showed however the need to use a certain number of Gauss-Hermite quadrature points to approximate the
integral over the random effects. Indeed, the use of 3 pseudo-adaptative Gauss-Hermite quadrature points
induced a bias in the estimation of the parameters associated with time effect in the longitudinal sub-part.
This error was fully corrected with 9 points. Overall, these results confirmed the good performances of
the implemented procedure. Complementary simulation results based on 500 and 1000 subjects are
provided in Appendix A.
5 Application
We analysed data from patients with localized prostate cancer and treated by external beam radiotherapy.
The analysis aimed to explore the link between PSA dynamics and transition intensities between clinical
states, as well as to describe PSA repeated measurements and times of transitions between health states.
5.1 Data description
Our study focuses on 1474 men with a clinically localized prostate cancer and treated by external beam
radiotherapy (EBRT): 629 patients come from the multi-center clinical trial RTOG 9406 (Radiation
Therapy Oncology Group, USA) in which data collection has been conducted from 1994 to 2013, and
845 patients come from the cohort of the British Columbia Cancer Agency (BCCA) in Vancouver,
Canada, and have been examined between 1994 and 2012 (Table 2). During his follow-up, a patient can
possibly go through several states defined as local recurrence, distant recurrence, initiation of hormonal
therapy (HT) and death, due or not to prostate cancer. The initiation of salvage hormonal therapy,
which is an additional treatment prompted by physician observed signs in PSA or clinical signs, is
designed to prevent growth of potentially present subclinical cancer. This intervention is not planned
at diagnosis or initiated by any precise rule, but is rather based on a mutual agreement between the
11
clinician and his patient. Thus, it is treated as a disease state transition representing failure of the initial
treatment to satisfactorily control the disease. Furthermore, as recommended in the article by Proust-
Lima et al. (2008), we only considered the local relapses which took place three years or later after
radiation, or within three years of EBRT when the last PSA value was > 2 ng/ml. PSA data were
collected at regular visits, for a median number of 10 PSA measurements per patient. Note that this
number includes only PSA data recorded between the end of EBRT and before the first event (first
clinical recurrence, hormonal therapy, death or censorship). Subjects with only one PSA measure were
excluded, and subjects who had an event in the first year after EBRT were excluded to prevent inclusion
of patients who had substantial residual initial tumors. As shown in Table 2, three baseline factors
were considered: the pre-therapy level of PSA in the log scale (iPSA), the T-stage category which
characterizes the tumour size (3 categories were considered: 2, 3–4 versus 1 in reference), and the
Gleason score category which measures the aggressiveness of cancer cells (3 categories: 7, 8–10 versus
2–6 in reference). In the models, a cohort covariate was also considered coded as 1 for RTOG 9406 and
−1 for BCCA. More details on the RTOG 9406 trial can be found in Michalski et al. (2005), and on the
BCCA cohort in Pickles et al. (2003).
[Table 1 about here.]
The PSA individual trajectories collected between the end of EBRT and the occurrence of the first
event are depicted in Figure 2. Overall, this longitudinal process is biphasic, with a decrease in the
level of PSA in the first years following the end of EBRT, and a subsequent stabilisation or linear rise
thereafter. According to the type of first relapse, the biomarker’s long-term increase may have different
intensities (see “Hormonal Therapy” and “Censorship” for example).
[Figure 2 about here.]
The multi-state data are depicted through the transitions between the 5 states and the corresponding
amount of observed direct transitions in Figure 3.
[Figure 3 about here.]
From the end of EBRT (state 0), a patient can experience either a transition to a localized recurrence
(state 1), an hormonal therapy (state 2), a distant recurrence (state 3) or death (absorbing state 4). After
12
a localized recurrence (state 1), a patient may experience either a distant recurrence (state 3) or die (state
4) or initiate a HT (state 2). After initiation of HT, a patient may only experience a distant recurrence
or die, and finally, after a distant recurrence, a patient may only die. In total, 144 subjects had a local
recurrence; 317 men initiated an hormonal therapy including 90 after a local recurrence; 90 men had
a distant recurrence including 10 directly after a local recurrence and 33 after a HT initiation. In total,
802 patients died including 523 who did not have another recorded progression of the cancer before.
Among the 672 men who were censored during the follow-up, 533 were censored before experiencing
any clinical progression.
5.2 Specification of the joint model
The joint multi-state model being a complex model, a step-by-step procedure was carried out to specify
the joint model. The specifications of the longitudinal and multi-state sub-models were based on two
separate analyses, that is assuming independence between the two processes. Covariate selection was
made using uni- or multivariate Wald tests.
5.2.1 Longitudinal sub-model specification
The biphasic shape of log-PSA was described in a linear mixed model with two functions of time accord-
ing to previous works (Proust-Lima et al., 2008): f1(t) = (1 + t)α − 1 and f2(t) = (t)1+ν /(1 + t)ν, where
α and ν were estimated by profile likelihood (α = −1.2, ν = 0). Thus, these two functions depicted
respectively the short term drop in the level of log-PSA after EBRT and the long term linear increase
of log-PSA. By denoting Yi j = log
(
PSAi(ti j) + 0.1
)
the log-measure of PSA for the individual i at time
ti j –the natural logarithm transformation is performed to obtain a Gaussian shape for the longitudinal
response– the linear mixed sub-model took the form:
Yi j = Y∗i (ti j) + i j
=
(
β0 + XL0 >i β0,cov + bi0
)
+(
β1 + XL1 >i β1,cov + bi1
)
× f1(ti j) +(
β2 + XL2 >i β2,cov + bi2
)
× f2(ti j) + i j,
13
with bi = (bi0, bi1, bi2)> ∼ N (0,D), D unstructured, and i = (i1, . . . , ini)> ∼ N(0, σ2Ini). The covari-
ates XL0i , X
L1
i and X
L2
i were sub-vectors of the baseline prognostic factors obtained using a backward
stepwise procedure. For the sake of brevity, we will speak about PSA dynamics and biomarker’s cur-
rent level/slope when referring actually to respectively the dynamics of log(PSA + 0.1) and the current
level/slope of Y∗i (t).
5.2.2 Multi-state sub-model specification
In the multi-state sub-part, the determination of prognostic factors and proportionality between baseline
intensities was also made by considering no link between the two processes (η = 0) and unspecified base-
line intensities (i.e. using a standard semi-parametric multi-state model). The full sub-model considered
transition-specific baseline intensities and transition-specific effects of baseline prognostic factors. To
reduce the excessive number of parameters to estimate, a first step was to assume proportional baseline
intensities for some transitions. Clinically, it made sense to consider proportional baseline intensities for
transitions leading to local recurrence or hormonal therapy: λ01,0(t) = exp(ζ02)λ02,0(t) = exp(ζ12)λ12,0(t);
and for the transitions leading to distant recurrence: λ03,0(t) = exp(ζ13)λ13,0(t) = exp(ζ23)λ23,0(t). These
assumptions were confirmed by the data. We could not make the same assumption for all transitions
leading to death because the proportional hazards assumption was not verified. Instead, we chose
λ14,0(t) = exp(ζ24)λ24,0(t) and λ04,0(t) was stratified on the cohort. This procedure reduced the num-
ber of baseline intensities to six. A second step consisted in selecting the prognostic factors. Factors
with an associated p-value > 0.5 were removed, and common covariate effects on several transitions
were considered using multivariate Wald tests. For example, the baseline T-stage category had the same
effect on transition intensities 0 → 1, 0 → 3 and 2 → 3. Finally, covariates with p-value < 0.1 were
selected by using a backward stepwise procedure.
5.2.3 Joint multi-state model specification
In the joint model, log baseline intensities approximated by linear combinations of cubic B-splines with
three internal knots replaced the unspecified ones. The dependence function Whk,i(bi, t) was the same
for all the transitions h → k and was determined using Wald tests. It resulted that the combination of
the true current level and the true current slope of the biomarker fitted at best the relationship between
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PSA dynamics and the instantaneous risk to transit between health states. The final step was to select the
prognostic factors and the log-coefficients of proportionality between baseline intensities with p-value <
0.1 in the multi-state sub-part by using a backward stepwise procedure. Thus, the multi-state sub-model
was:
λihk(t|bi) = λhk,0(t) exp
XS >hk,i γhk +
 Y
∗
i (t)
∂Y∗i (t)/∂t

> ηhk,levelηhk,slope

 ,
where the relations between λhk,0(t) and the final XShk,i, for h, k ∈ {0, . . . , 5} are indicated in Section 5.2.2
and in Table 3. Note that the covariates that were removed of the joint model specification are not in
Table 3.
5.3 Results
The parameter estimates of the joint multi-state model are presented in Table 3. These parameters
were those selected according to the procedure described previously. The parameters of the baseline
intensities are not shown here for clarity.
[Table 2 about here.]
The estimated regression parameters in the longitudinal sub-part confirmed that pre-treatment PSA level
was associated with the initial PSA level and the biphasic PSA trajectory, T-stage value was associated
both with the short term and the long term dynamics while Gleason score was only associated with the
long term trajectory. Higher values of these covariates measured at baseline corresponded to higher long
term PSA levels. The cohort effect indicated a significant difference between the two cohorts only for
the long term PSA evolution, with a greater long term increase of PSA in Vancouver.
For the multi-state process, the prognostic factors showed that an advanced initial stage was not
always associated with the intensities of transitions between health states after adjustment for the PSA
dynamics. In particular, the Gleason score had significant effects on only two transition intensities.
Moreover, we found that having a high PSA value at baseline was significantly associated with a higher
instantaneous risk to directly experience hormonal therapy initiation or death after EBRT, but reduced the
intensities of transitions leading to distant recurrence or death after a previous event. A poor (i.e. higher)
T-stage category at baseline had globally a deleterious effect on the clinical endpoints. For the transitions
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leading to distant recurrence after EBRT or after hormonal therapy, a patient with a Gleason score of 7
at baseline had a 2.65 = exp(0.973) (95% CI = 1.64–4.28) higher hazard to transit than a patient with a
Gleason score < 7. The cohort was significantly associated with the intensities of transitions leading to
death after clinical recurrence or hormonal therapy –and the direct transition leading to local recurrence
after EBRT. The instantaneous risk to experience these transitions was higher in BCCA. For the direct
transitions leading to distant recurrence after local recurrence or hormonal therapy, the cohort effect was
also significant, with higher intensities in RTOG 9406.
Regarding the association parameters between PSA dynamics (current level and current slope) and
clinical progressions, there were highly significant deleterious effects of the PSA dynamics from the
initial state on the intensities of transitions leading to all the types of progression (local recurrence, hor-
monal therapy or distant recurrence). For example, after adjustments for covariates and for the true slope
of the biomarker, an increase of one unit of the true biomarker’s level (log PSA without error measure-
ment) induced a 1.45 = exp(0.372) (95% CI = 1.23–1.72) higher risk to experience a local recurrence.
These results were expected: in patients with localized prostate cancer and treated by radiotherapy, a per-
sistently high PSA level or/and a strong increase of PSA leads to higher hazard to experience a clinical
recurrence or an additional therapy. In contrast, for the direct transition leading to death after radiother-
apy, we found a deleterious effect of the current slope and a protective effect of the current level of the
biomarker: at a given moment in the initial state, for two patients with the same baseline characteristics
and the same slope of log PSA, the one with higher PSA value will be less likely to directly die. In
this studied population, an important cause of death is induced by comorbidities, most of death from
prostate cancer experienced a documented disease progression before. From the local recurrence, there
was large deleterious effect of the current slope of the biomarker for the intensities of transitions leading
to the hormonal therapy or the distant recurrence, and there was a borderline significant protective effect
of the current level for the intensity of transition leading to the distant recurrence. From the hormonal
therapy or the distant recurrence, there was no significant effect of the PSA dynamics on the hazard to
change state. This was also clinically sensible, as it reflects that progression in these advanced stages is
no more linked to PSA increase. In practice, criteria other than PSA are considered specifically in this
phase of the disease, such as the PCWG2 criteria (Scher et al., 2008). Moreover, deaths in patients with
hormonal therapy might be explained by cardiac toxicity due to HT.
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5.4 Diagnostics
The parameter estimates of the joint multi-state model were validated by several graphical tools pre-
sented in Figure 4. For the longitudinal sub-model, the plotted standardized conditional residuals versus
fitted values of the biomarker confirmed the homoscedasticity of the conditional errors. Subject-specific
predictions were also compared to observations by plotting the average values by time intervals based
on the deciles of the observation times. 95% confidence intervals of the observed values were added and
confirmed the very good fit of the model concerning the longitudinal data. For the multi-state sub-part,
we focused on P(0, t) = {Phk(0, t)} the matrix of transition probabilities between the times 0 and t. We
compared our parametric estimator (obtained through the average of the predicted individual transition
probabilities from the joint multi-state model) to the Aalen-Johansen estimator (non-parametric estima-
tor of the transition probabilities), both using product integrals. This comparison is fully discussed and
detailed in Appendix B. These comparisons showed the overall good performances of the joint multi-
state model in terms of fit of transition probabilities, with the exception for the transition 1 → 2 for
which the immediate pike after EBRT could not be correctly captured by splines.
[Figure 4 about here.]
6 Discussion
The joint model for the longitudinal biomarker PSA and multi-state clinical progression data provides
a full model of prostate cancer progression which takes into account both classical prognostic factors
and the dynamics of the PSA, in order to study factors that influence the transition intensities between
clinical health states. The implementation is easy and relies on the mstate and JM packages. The multi-
state data are prepared through the mstate package, and a slightly modified jointModel() function
carries out the estimation procedure. The estimation program has been validated by simulations, with
very good performances. It underlined however some bias in the estimates when too few quadrature
points (3) were used. In the absence of specific validation, we thus recommend at least 9 Gauss-Hermite
quadrature points in the pseudo-adaptative numerical integration to approximate at best the integral over
the random effects. Goodness-of-fit of the model can be assessed using diagnostic graphical tools whose
methodology was detailed in Appendix B.
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The application confirmed that the PSA dynamics strongly impacted the instantaneous risk to ex-
perience a clinical recurrence or hormonal therapy after the end of radiotherapy. Moreover, the current
slope of the biomarker had highly significant deleterious effect on the hazard to transit from local recur-
rence to hormonal therapy or distant recurrence. Conversely, extrapolating the biomarker’s dynamics did
not impact anymore the transition intensities from the hormonal therapy or the distant recurrence states.
This expresses that in the advanced cancers, the PSA –and especially the collected measures prior the
first event– is no more of importance. In these situations, other criteria have to be monitored.
Previous works in prostate cancer had found a strong association between slope of log-PSA and any
clinical recurrence (see Se`ne et al. (2014); Taylor et al. (2013)), by considering all the recurrences in a
composite event and the hormonal therapy as a time-dependent covariate. The limit of these approaches
was that in practice the type of progression is of major importance as the care greatly depends on the
type of risk the patient has. The joint multi-state model formalizes this need. In the same way as it
was done with a single event (see Proust-Lima and Taylor (2009); Rizopoulos (2011)), individualized
dynamic predictions of each type of progression could be derived from this model in order to precisely
quantify the risk of each type of progression according to the PSA history. For example, the cumulative
probability for subject i to reach the state k between the times s and t, s ≤ t, given he was in state h
at time s, could be expressed as: Fihk(s, t) =
∫ t
s Pr(Ei(u) = k|Ei(s) = h,Y (s)i , XL (s)i , XSi ) du, with Y (s)i the
history (i.e. collected measures) of the marker up to time s, XL (s)i the history of the longitudinal sub-part
covariates until time s, and XSi = {XShk,i} the matrix containing the prognostic factors for all the state
transitions.
In this article, we assumed a continuous and Markov multi-state process. Depending on the topic, a
semi-Markov process, which considers the spent time in the current state, could be defined as well. In
dementia for example, the multi-state process might consider three states: healthy, demented and dead,
and it would be necessary to consider the time spent in the demented state before death (Commenges
et al., 2007). The joint multi-state model and its associated implemented function handle for semi-
Markov.
In summary, we introduce here a first joint model for longitudinal and multi-state clinical progression
data. We showed that this model can easily be implemented under R and can be applied in practice
through an example, the prostate cancer progression, which is one of many biomedical areas in which
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such data are collected. This model that captures the complete information about the progression opens
to much more precise knowledge of diseases and specific dynamic predictions.
7 Appendix
Appendix A: Simulation results
In Section 4 in the article, the simulations were performed on 1500 subjects and showed that 9 Gauss-
Hermite quadrature points should be used in this case. A complementary simulation study was based
on the first 500 and 1000 individuals of each of the 500 replicates and used 9 Gauss-Hermite quadrature
points. With 500 and 1000 subjects, we respectively observed 167 and 333 transitions 0 → 1, 103 and
205 transitions 0→ 2, 96 and 191 transitions 1→ 2. The results are presented in Table 4.
[Table 3 about here.]
Overall, these results confirmed the good performances of the implemented function. The coverage
rates were close to 95% and the relative bias were low, except for γ02,X and η12,slope, certainly due to
the required accuracy.
Appendix B: Parametric versus non-parametric transition probabilities
To assess the results obtained in our application (Section 5 in the article), we compared the parametric
estimator of the transition probabilities to a non-parametric estimator. The following results are based
on the book of ?.
Preliminaries
Consider the multi-state process E = {E(t), t ≥ 0} with values in the finite space S = {0, 1, . . . ,M} and
where E(t) denotes the state occupied by an individual at time t. We assume that E is a non-homogeneous
Markov process, with left truncation and right censoring. In the following, we will consider that all the
introduced multi-state processes guarantee the above properties. The intensity of transition from state
h ∈ S to state k ∈ S at time t is defined as λhk(t) = limdt→0 Pr(E(t + dt) = k|E(t) = h)dt and we write
λ(s, t) = {λhk(s, t)} the (M + 1) × (M + 1) matrix of transition intensities. The matrix of cumulative
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transition intensities is noted Λ(t), composed of non-diagonal elements Λhk(t) =
∫ t
0 λhk(u) du,∀h , k,
and diagonal elements Λhh(t) = −∑k,h Λhk(t). Let us consider the transition probability Phk(s, t) =
Pr(E(t) = k|E(s) = h), with s ≤ t, which is the probability that a subject in state h at time s occupies the
state k at a later time t. We call P(s, t) = {Phk(s, t)} the matrix of transition probabilities, which satisfies
the Chapman-Kolmogorov equation:
P(s, t) = P(s, u)P(u, t), with 0 ≤ s ≤ u ≤ t. (8)
Thus is deduced that P(s, t) is the unique solution of the Kolmogorov forward differential equations:
P(s, s) = I,
∂
∂t
P(s, t) = P(s, t)λ(t).
(9)
Non-parametric estimator
Let Nhk(t) be the number of direct observed transitions from state h to state k up to time t, and Yh(t)
the number of individuals in state h just before time t. The non-parametric estimator of the cumulative
intensities, called Λ∗(t) has elements Λ∗hk(t) estimated through the Nelson-Aalen estimator:
Λ∗hk(t) =
∫ t
0
dNhk(u)
Yh(u)
, h , k, (10)
and Λ∗hh(t) = −
∑
k,h Λ
∗
hk(t). The solution to the Kolmogorov equations (9) permits to express the non-
parametric estimate of the transition probabilities P̂∗(s, t) though the product-integral:
P̂∗(s, t) =R
(s,t]
(
I + dΛ̂∗(u)
)
. (11)
where Λ̂∗(u) is the non-parametric estimate of the cumulative transition intensities at time u, with
dΛ̂∗hh(u) ≥ −1 for all u, and I is the (M + 1) × (M + 1) identity matrix. This estimated matrix of
transition probabilities is called Aalen-Johansen estimator.
Let s < T ∗1 < . . . < T
∗
m∗ ≤ t be the ordained times of observed direct transitions between s and t for
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all individuals. From (11), it can be deduced:
P̂∗(s, t) =
m∗∏
l=1
(
I + ∆Λ̂∗(T ∗l )
)
. (12)
where ∆Λ̂∗(T ∗l ) = Λ̂
∗(T ∗l ) − Λ̂∗(T ∗l−1) and ∆Λ̂∗hh(T ∗l ) ≥ −1 for all T ∗l .
In our application, we applied:
I + ∆Λ̂∗(T ∗l ) =

1 − ∆N0.(T
∗
l )
Y0(T ∗l )
∆N01(T ∗l )
Y0(T ∗l )
∆N02(T ∗l )
Y0(T ∗l )
∆N03(T ∗l )
Y0(T ∗l )
∆N04(T ∗l )
Y0(T ∗l )
0 1 − ∆N1.(T
∗
l )
Y1(T ∗l )
∆N12(T ∗l )
Y1(T ∗l )
∆N13(T ∗l )
Y1(T ∗l )
∆N14(T ∗l )
Y1(T ∗l )
0 0 1 − ∆N2.(T
∗
l )
Y2(T ∗l )
∆N23(T ∗l )
Y2(T ∗l )
∆N24(T ∗l )
Y2(T ∗l )
0 0 0 1 − ∆N3.(T
∗
l )
Y3(T ∗l )
∆N34(T ∗l )
Y3(T ∗l )
0 0 0 0 1

,
where Nh.(T ∗l ) =
∑
k,h Nhk(T ∗l ) and ∆Nhk(T
∗
l ) = Nhk(T
∗
l ) − Nhk(T ∗l−1).
Parametric estimator
For each patient i ∈ {1, . . . ,N}, the observed multi-state process is {Ei(t), t ≥ 0}, where Ei(t) denotes the
state occupied by subject i at time t and takes values in the finite space S = {0, 1, . . . ,M}. In our joint
multi-state model, we were interested in the transitions intensities:
λihk(t|bi) = limdt→0
Pr(Ei(t + dt) = k|Ei(t) = h; bi)
dt
, (13)
which share the random effects bi with the longitudinal sub-model. Based on the Preliminaries para-
graph, let Λi(t|bi) = {Λihk(t|bi)} be the parametric matrix of cumulative intensities for subject i, and
Pihk(s, t|bi) = {Pihk(s, t|bi)} be the parametric matrix of transition probabilities. From the individual co-
variates measured at baseline XShk,i and the parameters estimated by maximum likelihood θˆ, we computed
for each subject i the individual predictions of the transition intensities λ̂ihk(t|θˆ) and deduced the individ-
ual predictions of the cumulative intensities Λ̂ihk(t|θˆ). To obtain the parametric estimator of the individual
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transition probabilities P̂i(s, t|θˆ), we could use the relations:
P̂ihh(s, t|θˆ) = exp
(
Λ̂ihh(t|θˆ) − Λ̂ihh(s|θˆ)
)
,
P̂ihk(s, t|θˆ) =
∫ t
s
P̂ihh(s, u|θˆ)̂λihk(u|θˆ)P̂ikk(u, t|θˆ)du, h , k.
(14)
In practice, when the state space S is large, these integrals become too complex numerically. In the
application we therefore preferred to calculate P̂i(s, t|θˆ) through the product-integral:
P̂i(s, t|θˆ) =R
(s,t]
(
I + dΛ̂i(u)
)
, (15)
with dΛ̂ihh(u) ≥ −1 for all u. The matrix of transition probabilities P̂(s, t) was then deduced by averaging
over the N individual predictions:
P̂(s, t|θˆ) = 1
N
N∑
i=1
P̂i(s, t|θˆ). (16)
Covariance estimation of the non-parametric estimator
The covariance matrix of the Aalen-Johansen estimator of transition probabilities can be estimated by
the Greenwood-type estimator:
ĉov(P̂∗(s, t)) =
∫ t
s
P̂∗(u, t)> ⊗ P̂∗(s, u−)ĉov(dΛ̂∗(u))P̂∗(u, t)) ⊗ P̂∗(s, u−)>, (17)
where ⊗ denotes the Kronecker product and > denotes the vector transpose.
? simplified the computations in (17) using the recursion formula:
ĉov(P̂∗(s, t)) = {(I + ∆Λ̂∗(t))> ⊗ I}ĉov(P̂∗(s, t−)){(I + ∆Λ̂∗(t)) ⊗ I} +
{I ⊗ P̂∗(s, t−)}ĉov(∆Λ̂∗(t)){I ⊗ P̂∗(s, t−)}, (18)
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where
ĉov(∆Λ̂∗hk(t),∆Λ̂
∗
h′k′(t)) =

(Yh(t) − ∆Nh.(t))∆Nh.(t)
Yh(t)3
, for h = k = h′ = k′,
− (Yh(t) − ∆Nh.(t))∆Nhk′(t)
Yh(t)3
, for h = k = h′ , k′,
− (δkk′Yh(t) − ∆Nhk(t))∆Nhk′(t)
Yh(t)3
, for h = h′, h , k, h , k′,
0, for h , h′,
with δkk′ the Kronecker delta. Note that ĉov(P̂∗(s, t)) and ĉov(∆Λ̂∗(t)) are two (K + 1)2 × (K + 1)2
covariance matrices.
These results may be used to construct the 95% pointwise confidence intervals for the Aalen-
Johansen estimator:
exp
log P̂∗hk(s, t) ± 1.96
√
v̂ar(P̂∗hk(s, t))
P̂∗hk(s, t))
 .
Appendix C: Example of R Code
This example is based on the simulation study (see Section 4 in the article), with a non-homogeneous
Markov multi-state model which included three states and three transitions. The same covariate, called
X in the above code, impacted the longitudinal and survival processes, the longitudinal sub-model had
a random intercept and a random slope, the log baseline intensities were approximated using B-splines,
and the dependence between the two processes was explained through the true current level and the true
current slope of the biomarker.
The JMstateModel() function and several detailed examples are available on https://github
.com/LoicFerrer/JMstateModel/.
# Load the packages and the function to estimate joint multi-state models:
library(mstate)
library(JM)
source("JMstateModel.R")
# Import two databases which contain longitudinal and survival data:
load("data.RData")
###############################
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#### Longitudinal sub-part ####
###############################
# Linear mixed model:
lmeFit <- lme(fixed = Y ˜ (1 + times) * X,
data = data_long,
random = ˜ (1 + times) | id,
method = "REML",
control = list(opt = "optim"))
##############################
#### Multi-state sub-part ####
##############################
# Construct the 3*3 matrix of possible transitions:
tmat <- matrix(NA, 3, 3)
tmat[1, 2:3] <- 1:2
tmat[2, 3] <- 3
dimnames(tmat) <- list(from = c("State 0", "State 1", "State 2"),
to = c("State 0", "State 1", "State 2"))
tmat
# The transition ’0 -> 1’ is called ’1’,’0 -> 2’ is called ’2’ and
# ’1 -> 2’ is called ’3’.
# Define the covariate(s) in the multi-state sub-part:
covs <- "X"
# The ’msprep()’ function divides the survival database in order to have
# one line per transition at risk for each subject, with ’Tstart’ the
# entry time in the current state, and ’Tstop’ the time of transition or
# censorship; ’status’ denotes if the transition has been performed:
data_mstate <- msprep(time = c(NA, "time_of_state_1", "time_of_state_2"),
status = c(NA, "State 1", "State 2"),
data = data_surv,
trans = tmat,
keep = covs,
id = "id")
# ’expand.covs()’ permits to define the set of covariates which impacts
# each transition:
data_mstate <- expand.covs(data_mstate, covs,
append = TRUE, longnames = FALSE)
# Multi-state model with proportional hazards:
coxFit <- coxph(Surv(Tstart, Tstop, status) ˜
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X.1 + X.2 + X.3 + strata(trans),
data = data_mstate,
method = "breslow",
x = TRUE,
model = TRUE)
####################################
#### Joint multi-state sub-part ####
####################################
# Define the derivative of the fixed and random parts in the mixed model,
# and indicate which covariates are kept, for the dependency on the slope
# of the marker:
dForm <- list(fixed = ˜ 1 + X,
indFixed = c(2, 4),
random = ˜ 1,
indRandom = 2)
# Joint multi-state model with:
# - current level and current slope as dependence function,
# - adaptative cubic B-splines to approximate the log-baseline intensities,
# - 9 Gauss-Hermite quadrature points in the pseudo-adaptative numerical
# integration to approximate the integrals over random effects,
# - 3 Gauss-Kronrod quadrature points to approximate the integral over time.
jointFit <-
JMstateModel(lmeObject = lmeFit,
survObject = coxFit,
timeVar = "times",
parameterization = "both",
method = "spline-PH-aGH",
interFact = list(value = ˜strata(trans) - 1,
slope = ˜strata(trans) - 1,
data = data_mstate),
derivForm = dForm,
Mstate = TRUE,
data.Mstate = data_mstate,
ID.Mstate = "id",
control = list(GHk = 9, lng.in.kn = 3))
summary(jointFit)
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Figure 1: Simulated multi-state process. Arrows indicate the directions of the possible transitions. λhk(t)
characterizes the intensity of transition between states h and k at time t. The matrix Υsim has size (3, 3)
and is composed of elements Υsim,(h+1)(k+1), where Υsim,(h+1)(k+1) is the average number of observed
direct transitions h→ k over the 500 replicates. The diagonal elements Υsim,(h+1)(h+1) denote the average
number of patients who were censored in state h. Note that the sum of elements of a row (h + 1) of Υsim
corresponds to the average number of patients who experienced the state h.
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Figure 2: Individual trajectories of log (PSA + 0.1) after the end of EBRT and according to the kind of
first relapse in the two cohorts (N = 1474).
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Figure 3: Multi-state representation of the clinical progressions in prostate cancer. Arrows indicate the
directions of the possible transitions (N = 1474). λhk(t) characterizes the intensity of transition between
states h and k at time t. The matrix Υ has size (5, 5) and is composed of elements Υ(h+1)(k+1), where
Υ(h+1)(k+1) is the number of observed direct transitions h→ k. The diagonal elements Υ(h+1)(h+1) denote
the number of patients who were censored in state h. Note that the sum of elements of a row (h + 1) of
Υ corresponds to the number of patients who experienced the state h.
FIGURES 32
(a) Conditional standardized residuals versus the fitted val-
ues. The black curve indicates the mean of conditional
residuals according to the fitted values, using a locally
weighted polynomial regression.
(b) Observed and predicted values of the biomarker. 95%
confidence intervals of the observed values are connected
in grey.
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(c) Predicted transition probabilities from the joint multi-state model and non-parametric probability transitions.
Figure 4: Goodness-of-fit plots for the longitudinal process (a,b) and the multi-state process (c).
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Table 2: Description of the two cohorts.
Cohort RTOG 9406 BCCA Pooled
Study period 1994–2013 1994–2012
Number of patients 629 845 1474
Number of PSA measures per patient 13 (4, 23) 9 (3, 15) 10 (3, 21)
iPSA∗ 2.0 (1.0, 3.0) 2.1 (0.6, 3.3) 2.1 (0.8, 3.1)
Clinical T-stage
1 355 (56.4%) 184 (21.8%) 539 (36.6%)
2 261 (41.5%) 514 (60.8%) 775 (52.6%)
3–4 13 (2.1%) 147 (17.4%) 160 (10.9%)
Gleason score
2–6 424 (67.4%) 605 (71.6%) 1029 (69.8%)
7 167 (26.6%) 189 (22.4%) 356 (24.2%)
8–10 38 (6.0%) 51 (6.0%) 89 (6.0%)
Mean time of first event† 9.8 (2.3, 15.9) 7.7 (1.9, 14.1) 8.2 (2.0, 15.0)
Mean time of last contact‡ 11.6 (2.9, 16.7) 9.0 (3.4, 14.8) 9.7 (3.1, 15.9)
Continuous data: Median (5th and 95th percentiles).
Categorical data: Amount (percentage).
Times are in years since the end of EBRT.
∗ Pre-therapy PSA value (ng/ml) in the log(. + 0.1) scale.
† Minimum between the time of first transition and the time of censoring.
‡ Minimum between the time of death and the time of censorship.
FIGURES 34
Table 3: Parameter estimates, standard errors and p-values in the joint multi-state model on the pooled
data (N = 1474).
Longitudinal Process Multi-state Process
Value StdErr p-value Value StdErr p-value
β0 −0.26 0.06 < 0.001 γ02,iPSA 0.34 0.08 < 0.001
β0,iPSA 0.80 0.03 < 0.001 γ04,iPSA 0.27 0.08 < 0.001
β0,cohort −0.01 0.02 0.525 γ(13,14,23,24,34),iPSA −0.24 0.08 0.002
β1 0.71 0.13 < 0.001 γ(01,03,23),tstage2 0.91 0.18 < 0.001
β1,iPSA 0.89 0.06 < 0.001 γ(01,03,23),tstage3-4 0.73 0.23 0.002
β1,tstage2 0.38 0.08 < 0.001 γ(12,14,34),tstage2 −0.04 0.25 0.865
β1,tstage3-4 0.48 0.13 < 0.001 γ(12,14,34),tstage3-4 0.38 0.30 0.204
β1,cohort −0.04 0.04 0.333 γ(03,23)gleason7 0.97 0.24 < 0.001
β2 −0.24 0.04 < 0.001 γ(03,23)gleason8-10 0.09 0.43 0.827
β2,iPSA 0.19 0.02 < 0.001 γ(01,14,24,34),cohort −0.42 0.06 < 0.001
β2,tstage2 0.14 0.02 < 0.001 γ(13,23),cohort 0.89 0.17 < 0.001
β2,tstage3-4 0.26 0.04 < 0.001 ζ(12,13) 4.18 0.38 < 0.001
β2,gleason7 0.07 0.02 < 0.001 ζ23 3.03 0.52 < 0.001
β2,gleason8-10 0.22 0.04 < 0.001 η01,level 0.37 0.09 < 0.001
β2,cohort −0.06 0.01 < 0.001 η02,level 0.51 0.07 < 0.001
log(σ) −1.30 0.01 η03,level 0.45 0.11 < 0.001
η04,level −0.17 0.05 0.001
D11 0.37 0.02 η12,level −0.16 0.10 0.110
D12 0.01 0.01 η13,level −0.41 0.20 0.042
D13 0.35 0.03 η14,level 0.10 0.14 0.487
D22 0.14 0.01 η23,level −0.15 0.09 0.120
D23 0.25 0.02 η24,level 0.04 0.05 0.412
D33 1.68 0.09 η34,level 0.04 0.08 0.609
η01,slope 2.54 0.31 < 0.001
η02,slope 3.04 0.25 < 0.001
η03,slope 2.43 0.49 < 0.001
η04,slope 1.03 0.32 0.001
η12,slope 2.01 0.61 0.001
η13,slope 3.18 0.80 < 0.001
η14,slope −0.20 1.27 0.873
η23,slope 0.97 0.67 0.150
η24,slope 0.29 0.52 0.583
η34,slope −0.79 0.78 0.313
Di j denotes the i j-element of the covariance matrix for the random effects. γ(hk,h′k′),X denotes the effect
of the covariate X on the intensities of transitions h → k and h′ → k′, i.e.γ(hk,h′k′),X = γhk,X = γh′k′,X. In
the same idea, it is used ζ(12,13) = ζ12 = ζ13.
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Table 4: Simulation results on the 500 and 1000 first individuals of the 500 replicates and using 9 Gauss-
Hermite quadrature points. For each scenario, the statistics depicted are, from left to right: mean, mean
standard error, standard deviation, relative bias (in percentage) and coverage rate (in percentage).
500 subjects 1000 subjects
True Mean StdErr StdDev
Rel. Cov. Mean StdErr StdDev
Rel. Cov.
value bias rate bias rate
Longitudinal process
β0 −0.793 −0.797 0.085 0.086 0.4 94.8 −0.798 0.060 0.061 0.6 94.4
β0,X 0.543 0.544 0.039 0.040 0.2 94.8 0.545 0.028 0.029 0.3 95.8
β1 −0.096 -0.096 0.036 0.036 −0.2 96.0 −0.096 0.026 0.025 0.1 95.2
β1,X 0.027 0.027 0.017 0.017 −0.1 95.6 0.027 0.012 0.012 −0.1 95.2
log(σ) −0.737 −0.737 0.007 0.019 −0.1 96.0 −0.737 0.005 0.005 -0.0 93.0
Multi-state process
γ01,X 0.281 0.298 0.136 0.136 5.9 95.0 0.296 0.095 0.094 5.2 95.2
γ02,X 0.023 0.010 0.155 0.161 −57.9 93.0 0.028 0.108 0.112 21.6 93.8
γ12,X −0.169 −0.162 0.171 0.176 −4.3 94.6 −0.164 0.117 0.125 −3.1 94.8
η01,level 0.925 0.927 0.130 0.144 0.2 93.0 0.910 0.090 0.091 −1.6 94.6
η02,level 0.297 0.298 0.113 0.109 0.6 96.0 0.292 0.079 0.075 −1.5 95.6
η12,level 0.071 0.071 0.135 0.141 0.3 94.4 0.072 0.092 0.093 0.4 95.4
η01,slope 1.344 1.514 0.773 0.827 12.6 93.6 1.531 0.541 0.524 13.9 95.4
η02,slope −1.096 -1.071 1.125 1.119 −2.3 97.6 −1.041 0.788 0.737 −5.0 95.6
η12,slope 0.009 0.086 1.425 1.442 853.3 96.4 0.036 0.976 1.007 298.2 94.6
Random effects
D11 0.349 0.346 0.025 0.025 −0.8 95.0 0.347 0.017 0.017 −0.6 95.4
D12 −0.041 −0.042 0.008 0.008 0.3 95.0 −0.042 0.006 0.006 0.5 95.8
D22 0.062 0.062 0.004 0.005 −0.5 93.8 0.062 0.003 0.003 −0.2 92.6
